Twist Bioscience (TWST) Fundamental Analysis: Revenue, Earnings & Valuation

8.02 / 10

Outperform

Fundamentally, TWST rates Outperform with an 8.0/10 score. Strong points include PB‑ROE (1.9, group 4), Asset‑MV, Cash‑MV and a 20.3% YoY revenue growth. Weaknesses are revenue‑to‑market value and a 50.7% gross margin, dragging overall strength.

Analysis Checks(8/10)

Revenue-MV

Value-0.91

Score1/3

Weight17.77%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value20.32

Score3/3

Weight4.59%

1M Return1.54%

Inventory turnover ratio

Value7.08

Score2/3

Weight-3.31%

1M Return-1.21%

Gross profit margin (%)

Value50.72

Score0/3

Weight-17.25%

1M Return-7.24%

PB-ROE

Value1.90

Score3/3

Weight36.97%

1M Return9.74%

Income tax / Total profit (%)

Value-0.93

Score2/3

Weight3.15%

1M Return1.04%

Fixed assets turnover ratio

Value2.41

Score2/3

Weight-1.57%

1M Return-0.51%

Cost of sales ratio (%)

Value49.28

Score2/3

Weight-11.32%

1M Return-4.42%

Asset-MV

Value-0.55

Score3/3

Weight50.03%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight20.94%

1M Return5.94%

Is TWST undervalued or overvalued?

TWST scores 8.02/10 on fundamentals and holds a Discounted valuation at present. Backed by its -6.57% ROE, -19.56% net margin, -39.66 P/E ratio, 6.66 P/B ratio, and 62.43% earnings growth, these metrics solidify its Outperform investment rating.